"We'll want more patients and a longer follow-up to really make a call that the use of CRISPR is safe. But the data are certainly encouraging," Dr. Michel Sadelain, an immunologist at the Memorial Sloan Kettering Cancer Center in New York, told NPR. "So far, so good â€” but [it's] still early."